Irritable bowel syndrome is one of the most common reasons people see a GP, and most of it is genuinely manageable with medicines already familiar to any pharmacist. The catch is that IBS is a diagnosis of exclusion: symptoms that look like IBS can occasionally be something else, and a telehealth service has to know the difference before it starts prescribing antispasmodics on repeat.
Why IBS is a genuine opportunity, and a limited one
Irritable bowel syndrome affects a substantial share of adults at some point, with abdominal pain, bloating and altered bowel habit that fluctuates over months or years. Most patients have already tried over-the-counter remedies before they look for a service, and many simply want a faster route to a proper assessment and treatment plan than a lengthy GP wait allows.
The commercial model works because IBS is chronic and relapsing, so patients return for review and repeat supply rather than a single transaction. But the opportunity has a hard edge: IBS can only be diagnosed once more serious conditions have been reasonably excluded, and a service that skips that step is not managing IBS, it is guessing.
The diagnosis problem: Rome IV and what a remote service can confirm
NICE guideline NG61 and the internationally used Rome IV criteria both frame IBS around recurrent abdominal pain associated with a change in stool frequency or form, present for a minimum period and without a better explanation. A remote assessment can work through this criteria carefully, but it depends on a thorough history: onset, pattern, triggers, and what has already been tried or tested.
Where a patient has had no prior workup, especially a first presentation of new bowel symptoms in adulthood, the safer default is baseline blood tests, such as a full blood count, coeliac serology and inflammatory markers, and, where indicated, faecal calprotectin to help distinguish IBS from inflammatory bowel disease, rather than assuming IBS from symptoms alone. NICE NG61 sets out this same exclusion logic.
The red flags that take a case out of the pathway
NICE NG61 lists alarm features that should prompt referral rather than a diagnosis of IBS: unintentional weight loss, rectal bleeding, a family history of bowel or ovarian cancer, a change in bowel habit in someone over 60, iron-deficiency anaemia, or an abdominal or rectal mass. Any of these takes the case out of a remote IBS pathway.
New onset of symptoms in an older patient, or a pattern that does not fit typical IBS, deserves the same caution. The discipline is not treating symptoms that merely resemble IBS as if the label were itself a diagnosis; it is confirming that the picture genuinely fits before starting a management plan. Prescriber discretion applies throughout.
IBS is easy to over-simplify because the medicines are familiar and mostly available without prescription. The clinical value of the service is entirely in the exclusion step: confirming red flags are absent before treating symptoms as IBS, not after.
First-line treatment: antispasmodics, laxatives and anti-diarrhoeals
Once IBS is confirmed, treatment follows the patient's dominant symptom rather than a single protocol. Antispasmodics such as mebeverine or hyoscine butylbromide are typically first-line for cramping pain. For IBS with constipation, bulk-forming laxatives or macrogol-based products are usual; for IBS with diarrhoea, loperamide used as needed is standard, dosed to effect rather than on a fixed schedule.
None of these medicines are controlled drugs, which makes IBS a comparatively low-risk vertical operationally, but the assessment still needs to establish subtype: treating the wrong pattern, a laxative for someone with diarrhoea-predominant IBS, for instance, does real harm to trust in the service. Prescriber discretion applies to dose and choice throughout.
Diet, the low FODMAP approach, and second-line options
Dietary change is often as important as medication, and NICE recommends first-line advice on regular meals, fluid intake, and limiting caffeine, alcohol and fizzy drinks before anything more restrictive. Where symptoms persist, a structured low FODMAP elimination and reintroduction plan, ideally guided by a dietitian, is the recognised second step.
- Soluble fibre, such as ispaghula, in preference to insoluble bran, which can worsen symptoms.
- Peppermint oil capsules for pain and bloating, widely used as an adjunct.
- Low FODMAP diet, time-limited and reintroduced systematically, not followed indefinitely without guidance.
- Low-dose tricyclics, such as amitriptyline, used off-label for pain when first-line measures have not worked.
- Probiotics, trialled for a defined period since response is individual and inconsistent.
Weight loss, rectal bleeding, anaemia, a change in bowel habit after 60: these are not IBS to be managed with mebeverine. They take the patient out of the remote pathway and toward proper investigation.
Building the review cadence and documentation
IBS is a long-term relationship, not a one-off order, so the service needs a review cadence built in: has the diagnosis held up, has anything changed that reopens the exclusion question, and is the current treatment still working. That discipline should sit inside the same clinical SOPs and documentation standards that govern every other vertical.
Symptoms that were stable and then change pattern, or fail to respond to a reasonable trial of treatment, are a trigger to step back and re-check the red-flag list rather than simply switching medicines. Good records of that reasoning protect both the patient and the service if a case is reviewed later.
How PExpo supports an IBS launch
PExpo provides the regulated layer behind a telehealth brand: registered dispensing, prescriber governance, pharmacovigilance and the patient record, so an IBS service can launch on a compliant base with the exclusion and referral discipline built into how cases are assessed, not bolted on afterwards. Reflux is another everyday, medicine-familiar vertical with the same discipline; see our acid reflux and GORD guide for the parallel.
You bring the brand and the funnel; the clinical judgement on when a case is IBS and when it is not sits with an operator that runs this pathway routinely. See our brand model and pricing.
IBS rewards operators who treat the exclusion step as the real clinical work, not a formality: confirm the pattern fits, screen for red flags at every review, match treatment to subtype, and build diet and second-line options into the pathway rather than defaulting straight to medicine. See our launch checklist and brand model for the operational detail.
Frequently asked questions
Can IBS be diagnosed for the first time through a UK telehealth service?
Yes, provided the assessment works through the Rome IV criteria and NICE NG61's red-flag list before confirming the diagnosis. Where there is diagnostic uncertainty, a first presentation of new bowel symptoms, or any alarm feature, referral for further investigation is the safer route rather than treating the symptoms as IBS remotely.
What are the IBS red flags that need referral rather than treatment?
Unintentional weight loss, rectal bleeding, iron-deficiency anaemia, a new change in bowel habit in someone over 60, an abdominal or rectal mass, or a family history of bowel or ovarian cancer. NICE NG61 lists these as reasons to investigate rather than manage the case as IBS.
What medicines are used to treat IBS online in the UK?
Treatment is matched to the dominant symptom: antispasmodics such as mebeverine for pain, laxatives for constipation-predominant IBS, and loperamide for diarrhoea-predominant IBS, alongside dietary advice such as a low FODMAP approach. None of these are controlled drugs. Prescriber discretion applies to dose and choice.
